EU approves AstraZeneca’s COVID-19 vaccine as booster shot
- A Single US$2.15-Million Injection to Block 90% of Cancer Cell Formation
- WIV: Prevention of New Disease X and Investigation of the Origin of COVID-19
- Why Botulinum Toxin Reigns as One of the Deadliest Poisons?
- FDA Approves Pfizer’s One-Time Gene Therapy for Hemophilia B: $3.5 Million per Dose
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
EU approves AstraZeneca’s COVID-19 vaccine as booster shot
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
EU approves AstraZeneca’s COVID-19 vaccine as booster shot.
On May 23, British/Swedish multinational pharmaceutical company AstraZeneca said that its COVID-19 vaccine Vaxzevria has been approved by the European Medicines Agency (EMA) as a booster vaccine for adults.
Last Thursday, AstraZeneca’s COVID-19 vaccine booster (clinical trial data) received a positive assessment from the European Committee for Medicinal Products for Human Use (CHMP).
AstraZeneca said in a statement on Monday that the company’s COVID-19 vaccine can be used as a booster shot for the first two doses of the Vaxzevria COVID-19 vaccine, as well as other messenger ribonucleic acid (mRNA) produced by companies such as Pfizer/BioNTech or Moderna. A booster shot of the COVID-19 vaccine.
The European Medicines Agency concluded that there was “substantial evidence” of an enhanced immune response following the administration of the Vaxzevria vaccine co-developed with the Oxford conference as a third booster dose, the statement said.
Despite a 40% drop in sales in Europe, where the outbreak is under control following the vaccination, AstraZeneca announced last month that sales of Vaxzevria quadrupled to US$1.15 billion in the first quarter. .
But AstraZeneca also warned in April that COVID-19 revenue, including Vaxzevria, would decline this year as the health crisis subsides.
Information about Vaxzevria
Vaxzevria is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older. COVID-19 is caused by SARS-CoV-2 virus.
Vaxzevria is made up of another virus (of the adenovirus family) that has been modified to contain the gene for making a protein from SARS-CoV-2.
Vaxzevria does not contain the virus itself and cannot cause COVID-19.
Detailed information about this vaccine is available in the product information, which includes the package leaflet.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
